We've updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience, read our Cookie Policy
EP29306
Abstract: The contaminating DNA can originate from the PCR reagent manufacturing environment, raw materials, human operators, or host cells expressing recombinant proteins. The main source of DNA contamination is the enzyme used for PCR, i.e.,Taq DNA polymerase. Reported DNA removal methods vary in efficiency and may decrease the sensitivity of the assay. We introduce InvitrogenTM PlatinumTM Taq DNA Polymerase, DNA-free – a PCR enzyme with the lowest DNA contamination levels as compared to competing “DNA-free” enzymes. This was achieved through manufacturing innovation, where the enzyme is produced using a closed single-use system (SUS) to minimize the risk of DNA contamination inherent to the conventional manufacturing process.Summary: Polymerase chain reaction (PCR) technology, used for PCR-based assays, is fast, sensitive, and specific; however, uncontrolled DNA contamination in assays could compromise sensitivity and specificity.References: We would like to thank Eglė Merkienė for her support in
development of Platinum Taq DNA polymerase, DNA-free.
development of Platinum Taq DNA polymerase, DNA-free.
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Related Posters
How to explore cancer-related mutations using NGS
CD Genomics
Improving the Chemical Synthesis and Performance of Extended-Length Guide RNAs for Genome Editing and Control of Gene Expression
Laurakay Bruhn, Bo Curry, Rob Kaiser, Ben Lunstad, Ryan McCaffrey, Joel Myerson, Subhadeep Roy, Daniel Ryan, Israel Steinfeld, David Taussig, Justin Townsend, Suhani Thakker, Doug Dellinger
Modulating the Activity of CRISPR-Cas with Chemical Modifications in Single-Guide RNAs
Daniel Ryan, David Taussig, Suhani Thakker, Israel Steinfeld, Ben Lunstad, Rob Kaiser, Ryan McCaffrey, Justin Townsend, Patrick Chaffey, Bo Curry, Doug Dellinger, Laurakay Bruhn
The Reasons for Choosing Our Cancer Panels - CD Genomics
CD Genomics
Build A Gene Mutation Panel with Non-NGS Technologies - CD Genomics
CD Genomics